1237 ET - Jazz Pharmaceuticals' move to buy Chimerix could be the start of deal-making by the biopharma, analysts at Piper Sandler say. Piper's David Amsellem and Alex von Riesemann say the $935 million deal is a sensible and targeted use of capital that doesn't get in the way of Jazz's ability to execute on additional M&A and doesn't entail Jazz taking on development risk. Piper notes that Jazz management has previously touted capacity for a multi-billion-dollar transaction or series of deals, and the analysts say they would like to see Jazz turn its attention to bolstering its epilepsy franchise. Jazz up 2% to $141.67. (colin.kellaher@wsj.com)
(END) Dow Jones Newswires
March 05, 2025 12:37 ET (17:37 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。